Published in J Pathol on May 01, 2009
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One (2010) 1.97
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One (2010) 1.41
A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Adv Urol (2012) 1.16
DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol (2013) 1.05
Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells. Carcinogenesis (2012) 0.97
Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol (2015) 0.94
A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc (2012) 0.89
Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours. PLoS One (2014) 0.87
TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Oncologist (2015) 0.84
Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood. PLoS One (2012) 0.77
Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence. Res Rep Urol (2012) 0.76
PTTG1 regulated by miR-146-3p promotes bladder cancer migration, invasion, metastasis and growth. Oncotarget (2016) 0.75
Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget (2016) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol (2010) 3.79
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol (2012) 3.34
Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology (2002) 2.87
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat (2009) 2.76
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol (2008) 2.66
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol (2008) 2.65
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res (2007) 2.32
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol (2006) 2.24
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res (2005) 2.19
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol (2011) 2.11
Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol (2008) 2.06
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol (2009) 2.02
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol (2007) 2.02
Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol (2008) 2.02
Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol (2013) 2.01
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One (2010) 1.97
Exosomes as biomarker treasure chests for prostate cancer. Eur Urol (2010) 1.94
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol (2008) 1.94
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer (2005) 1.93
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol (2007) 1.89
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res (2006) 1.83
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol (2007) 1.72
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet (2002) 1.72
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res (2008) 1.68
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res (2005) 1.68
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol (2010) 1.66
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int (2012) 1.62
Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol (2010) 1.61
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol (2008) 1.58
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol (2003) 1.58
Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol (2007) 1.57
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol (2006) 1.54
Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol (2010) 1.54
Cell type-specific hypersensitivity to oxidative damage in CSB and XPA mice. DNA Repair (Amst) (2003) 1.53
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. Eur Urol (2012) 1.52
Anxiety and distress during active surveillance for early prostate cancer. Cancer (2009) 1.49
A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients. Res Rep Urol (2012) 1.48
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int (2009) 1.46
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol (2007) 1.45
FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies. J Urol (2012) 1.44
Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol (2006) 1.42
Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett (2011) 1.41
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer (2009) 1.41
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One (2010) 1.41
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet (2012) 1.40
The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol (2007) 1.39
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res (2004) 1.38
The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene (2003) 1.38
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol (2006) 1.37
Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology (2010) 1.36
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst (2013) 1.32
Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms. Arch Pathol Lab Med (2011) 1.31
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol (2011) 1.29
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes (2009) 1.29